Among the most popular portfolio startups of the fund, we may highlight dMed. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Medical.
The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2016. Deals in the range of 5 - 10 millions dollars are the general things for fund.
The usual cause for the fund is to invest in rounds with 3 partakers. The meaningful sponsors for the fund in investment in the same round are ZAI Lab, Qiming Venture Partners. In the next rounds fund is usually obtained by Vivo Capital, Qiming Venture Partners, Lilly Asia Ventures.
| Fund Name | Location |
| 500 Kobe | - |
| Axis Capital | India, Maharashtra, Mumbai |
| Chip One Stop | Japan, Kanagawa Prefecture, Yokohama |
| CMG-SDIC Capital Management | Beijing, Beijing, China |
| Coagulare Biomedica | - |
| Collab Capital | Atlanta, Georgia, United States |
| Hitachi Global Life Solutions | Japan, Shibuya |
| Jianmin Pharmaceuticals | - |
| Korea Venture Capital Association (KVCA) | Seoul, Seoul-t'ukpyolsi, South Korea |
| Linear Capital Partners | California, Los Angeles, United States |
| Menomadin Foundation | - |
| Nanabianca | Florence, Italy, Toscana |
| Nanyang Ventures | Australia, New South Wales, Sydney |
| Perpetual Ventures | - |
| Rukam Capital Trust | Kyonggi-do, Seongnam, South Korea |
| Shinsegae I&C | - |
| Sylebra Capital | - |
| SZZT Electronics | China, Guangdong Province, Huizhou |
| Transference Fund | China, Shanghai |
| Wonderful Sky Financial Group | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
dMed | $8M | 01 Dec 2016 | Shanghai, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
dMed | $8M | 01 Dec 2016 | Shanghai, China |
